Connection

Marina Caskey to Antibodies, Neutralizing

Back to Details
This is a "connection" page, showing publications Marina Caskey has written about Antibodies, Neutralizing.
Marina Caskey
Connection Strength
0.670
Antibodies, Neutralizing
  1. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nat Med. 2019 04; 25(4):547-553.
    View in: PubMed
    Score: 0.115
  2. Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection. Curr Opin HIV AIDS. 2018 07; 13(4):366-373.
    View in: PubMed
    Score: 0.109
  3. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat Med. 2017 Feb; 23(2):185-191.
    View in: PubMed
    Score: 0.098
  4. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021 07; 595(7867):426-431.
    View in: PubMed
    Score: 0.033
  5. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci Transl Med. 2021 01 20; 13(577).
    View in: PubMed
    Score: 0.032
  6. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med. 2020 11 02; 217(11).
    View in: PubMed
    Score: 0.032
  7. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020 10 28; 9.
    View in: PubMed
    Score: 0.032
  8. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Cell. 2020 08 20; 182(4):828-842.e16.
    View in: PubMed
    Score: 0.031
  9. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020 08; 584(7821):437-442.
    View in: PubMed
    Score: 0.031
  10. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature. 2018 09; 561(7724):479-484.
    View in: PubMed
    Score: 0.028
  11. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat Med. 2018 11; 24(11):1701-1707.
    View in: PubMed
    Score: 0.028
  12. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. J Virol. 2018 03 01; 92(5).
    View in: PubMed
    Score: 0.027
  13. Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico. Cell. 2017 May 04; 169(4):597-609.e11.
    View in: PubMed
    Score: 0.025
  14. TOP-Plus Is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability. Clin Chem. 2021 09 01; 67(9):1249-1258.
    View in: PubMed
    Score: 0.008
  15. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity. 2021 08 10; 54(8):1853-1868.e7.
    View in: PubMed
    Score: 0.008
  16. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nat Commun. 2021 07 07; 12(1):4196.
    View in: PubMed
    Score: 0.008
  17. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021 04; 592(7855):616-622.
    View in: PubMed
    Score: 0.008
  18. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021 03; 591(7851):639-644.
    View in: PubMed
    Score: 0.008
  19. Relationship between intact HIV-1 proviruses in circulating CD4+ T cells and rebound viruses emerging during treatment interruption. Proc Natl Acad Sci U S A. 2018 11 27; 115(48):E11341-E11348.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.